Dexamethasone
[대역어] 덱사메타손
[용어속성] Drug
[용어속성] Drug
Repurposing existing drugs for COVID-19: an endocrinology perspective
Correspondence
[키워드] absence
ACE inhibitor
ACE2
affected
Ageusia
aging
androgen
angiotensin receptor blocker
angiotensin-converting enzyme-2
Anosmia
Anti-androgen
ARB
arthralgia
assessment
candidate
caused
Clinical effect
clinical testing
clinical trial
coronavirus 2
correlated
COVID-19
COVID-19 patient
death
description
Dexamethasone
diabetes
drug
drug treatment
effective therapy
Efficacy
elicited
Endocrine
Evidence
familiarity
fatigue
Fever
Glucocorticoids
heterogeneous
Hospitalization
hypertension
include
Infection
inherent
inhibitor
lack
less
mechanical ventilation
methodological
Mild-to-moderate
myalgia
N-acetyl cysteine
NAC
obesity
Other
outcome
pandemic
patients
Perspective
public health systems
RAAS
reduce mortality
reduction in
repurposing
Research
researcher
respiratory
risk
Safe
safety profile
SARS-CoV-2
severe COVID-19
severely ill patient
Symptom
target
therapeutic options
TMPRSS2
transmembrane serine protease
while
with COVID-19
worse prognosis
[DOI] 10.1186/s12902-020-00626-0 PMC 바로가기 [Article Type] Correspondence
[DOI] 10.1186/s12902-020-00626-0 PMC 바로가기 [Article Type] Correspondence
Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review
바이러스 수명 주기의 진입 후 단계를 대상으로 하는 잠재적인 Anti-SARS-CoV-2 치료제: 종합 검토
Review
[키워드] (RdRp
breath
chemical structures
clinical investigation
clinical trial
clinical trials
clinically
Comprehensive
coronavirus
coronavirus disease
COVID-19
decrease
described
Dexamethasone
dihydroorotate dehydrogenase
early stage
Effect
effective
EIDD-2801
facilitate
Favipiravir
Health care
Health care system
health care systems
identify
include
Infection
life
life cycle
limit
M pro
main protease
mechanism
molecular
monoclonal antibodies
mortality rate
pandemic
Papain-like protease
pharmaceutical companies
polypeptides
Potential
presenting
Prevent
protease
RdRP
Remdesivir
Research
review
RNA-dependent RNA polymerase
SARS-CoV-2
scientist
severity of COVID-19
Small molecules
Stage
Structure
target
Therapeutics
Treatment
Viral
viral infection
viral life cycle
Viral protein
Viral proteins
Viral RNA
viral RNA-dependent RNA polymerase
[DOI] 10.3390/v12101092 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/v12101092 PMC 바로가기 [Article Type] Review
Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials
Perspective Piece
[키워드] Anecdotal
caused
clinical
Clinical efficacy
Compound
compounds
COVID-19
COVID-19 pandemic
deaths
demonstrated
derivative
derivatives
develop
Dexamethasone
Efficacy
effort
evaluate
event
Evidence
fevers
herbal compound
herbal medicines
highlight
immunological effects
malaria
Map
pharmacological
Potential
Prevent
Randomized controlled trial
RCTs
Remdesivir
reported
Repurposed drug
Research
Respiratory tract infections
road
SARS-CoV-2
seriously ill patients
subsequent
treat
Treatment
[DOI] 10.4269/ajtmh.20-0820 PMC 바로가기 [Article Type] Perspective Piece
[DOI] 10.4269/ajtmh.20-0820 PMC 바로가기 [Article Type] Perspective Piece
Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain
Article
[키워드] Anakinra
analyzed
Anticoagulant treatment
anticoagulation
Antiviral
antiviral agent
antiviral drug
Antiviral treatment
clinical
clinical protocol
clinical risk factor
Combination
Combined
Coronavirus disease 2019
Corticosteroid
Corticosteroids
COVID-19
Critical
critical condition
Dexamethasone
difference
differences
different dose
discharge
Evidence
FIVE
heparin
high risk
high-risk patient
hospital
Hydroxychloroquine
hydroxychloroquine plus azithromycin
management
Methylprednisolone
Mild
mild respiratory
moderate
monotherapy
novel coronavirus disease
Patient
Pneumonia
Prednisone
Prophylactic
prophylactic dose
protocol
protocols
randomized clinical trial
recommendation
regimens
Seven
severe pneumonia
Spain
supportive care
therapeutic dose
Therapies
therapy
Thromboembolism
thrombosis
Treatment
[DOI] 10.3390/ijerph17186845 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/ijerph17186845 PMC 바로가기 [Article Type] Article
Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
COVID-19 치료를 위한 중재: 메타 분석 및 시험 순차 분석을 통한 살아있는 체계적인 검토(The LIVING Project)
Research Article
[키워드] 95% CI
95% confidence interval
acute respiratory syndrome
acute respiratory syndrome coronavirus
Admission
adverse event
adverse events
aggregate data meta-analyses
all age group
all age groups
all-cause mortality
assessment
caused
certainty
certainty of evidence
Clinical effect
Clinical research
Clinical significance
clinical trials
Cochrane guidelines
Comparisons
conducted
convalescent plasma
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19 patients
database
development
Dexamethasone
driven by
Effect
Evidence
evidence of
experimental intervention
Families
GRADE
high risk
Hydroxychloroquine
individual patient data meta-analyses
individuals
Infection
intensive care
International
Intervention
Intervention effects
item
Juul
lack
life
Lopinavir
Lopinavir–ritonavir
mechanical ventilation
meta-analyses
Meta-analysis
Network meta-analysis
no effect
no effects
no evidence of
nonserious adverse event
nonserious adverse events
on mechanical ventilation
outbreak
outcome
outcomes
participant
Participants
Patient
patient data
paucity of data
performed
Placebo
Primary outcomes
Quality of life
random errors
random-effects meta-analyses
randomized clinical trial
randomized clinical trials
rapidly spreading disease
rate ratio
reduce
reduced
reducing
Remdesivir
renal replacement therapy
replacement therapy
Reporting
Research
researcher
respiratory
Respiratory failure
review
risk
risk of bia
risk of death
risk ratio
Ritonavir
SARS-CoV-2
searched
secondary
Secondary outcomes
Serious Adverse Event
Serious Adverse Events
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
single trial
single trial randomizing
Sophie
Spread
standard care
statistically significant
systematic review
systematic reviews
Treatment
treatment for COVID-19
treatment intervention
treatment of COVID-19
treatments for COVID-19
treatments of COVID-19
Trial
Trial methodology
trial randomizing
trial sequential analyses
trial sequential analysis
website
with COVID-19
[DOI] 10.1371/journal.pmed.1003293 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1371/journal.pmed.1003293 PMC 바로가기 [Article Type] Research Article
Overview of the Pathogenesis and Treatment of SARS-CoV-2 for Clinicians: A Comprehensive Literature Review
Internal Medicine
[키워드] ACE2
acute respiratory syndrome
addition
angiotensin-converting enzyme 2
anticoagulation
articles
case sery
chloroquine/hydroxychloroquine
clinical trials
Clinicians
Comprehensive
conserved
Containment
coronavirus
country
covid induced ards
COVID-19
COVID-19 management
COVID19
described
Dexamethasone
disease
furin
immune-based therapies
include
information
knowledge
literature
measure
Novel coronavirus
pathogen
Pathogenesis
pathogenesis of SARS-CoV-2
presenting
produced
Proteases
receptor
Remdesivir
review
SARS-CoV-1
SARS-CoV-2
sars-cov-2 induced ards
SARS-COV-2 infection
SARS-CoV-2 pathogenesis
SARS-CoV-2 treatment
Scientific community
sequence
similarity
Spread
the S protein
Topic
transmembrane
Treatment
virus
WHO
WHO’
World Health Organization
worldwide pandemic
Wuhan, China
[DOI] 10.7759/cureus.10357 PMC 바로가기 [Article Type] Internal Medicine
[DOI] 10.7759/cureus.10357 PMC 바로가기 [Article Type] Internal Medicine
Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia
SARS-CoV-2 폐렴에 대한 면역억제 치료 중 나타난 Strongyloides 감염
Case Reports
[키워드] abdominal pain
bilateral pneumonia
Complication
Corticosteroid
Corticosteroids
Course
cytokine
cytokine inhibitor
cytokine inhibitors
Dexamethasone
eosinophil
Eosinophil count
Evidence
full recovery
High dose
High-dose
Hyperinflammatory
Immunosuppression
immunosuppressive
Immunosuppressive agents
immunosuppressive therapy
Infection
infections
interstitial
intravenous
intravenous dose
involved
Italian
itching
Ivermectin
Latent infections
manifested
Pathogenesis
Patient
Pneumonia
public health
Reactivation
risk
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 pandemic
SARS-CoV-2 pneumonia
severe COVID-19
severe disease
steroid
Steroids
Stool examination
Strongyloides stercoralis
strongyloidiasis
suggested
therapy
Tocilizumab
treated
Treatment
[DOI] 10.1007/s15010-020-01522-4 PMC 바로가기 [Article Type] Case Reports
[DOI] 10.1007/s15010-020-01522-4 PMC 바로가기 [Article Type] Case Reports
COVID-19 therapy and prevention
Review Article
[키워드] activities
antimicrobial agent
caused
Chloroquine
collected
Combination
comparison
coronavirus
COVID-19
Dexamethasone
diagnosed
disease
effective
Efficacy
effort
epidemiological
Evidence
Evolution
Favipiravir
Government
Hydroxychloroquine
immunomodulators
information
interferon
Mask
measure
New coronavirus
other coronaviruses
outbreak
Outbreaks
pandemic
Perspective
Pneumonia
provide
provided
question
raised
Remdesivir
Respirator
SARS-CoV-2
SARS-CoV-2 remdesivir
similarity
starting point
Support
the mean
therapeutic
Therapies
therapy
Tocilizumab
Transmissibility
Vaccine
Vaccines
virus
[DOI] 10.15190/d.2020.10 PMC 바로가기 [Article Type] Review Article
[DOI] 10.15190/d.2020.10 PMC 바로가기 [Article Type] Review Article
Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?
Review
[키워드] “cytokine storm”
adopted
alveolar
anti-inflammatory drug
Antiviral
ARDS
benefit
cause
CCL-2
Chloroquine
Combination
Control
Controlled
COVID-19
COVID-19 case
COVID-19 patient
COVID-19 treatment
cytokine
Cytokine storm syndrome
death
deaths
Dexamethasone
effective
Efficacy
Evidence
Evidence Based Medicine
FDA
gold
hospital
Hospitalized
hospitalized patients
Hydroxychloroquine
IL-12
IL-6
IL-8
immunological
include
indication
Lopinavir
Lopinavir—ritonavir
lung damage
mechanically ventilated
NIH
non-randomized
offer
patients hospitalized
patients receiving oxygen
patients with COVID-19
performed
Pharmacologic
provide
provided
RCT
RCTs
reduced
reducing
reducing mortality
Remdesivir
reported
respiratory
retrospective
SARS-CoV-2
SARS-CoV-2 pneumonia
service
Severe case
Standard
the disease
the WHO
therapy
therapy for COVID-19
TNFα
Treatment
treatment for COVID-19
Trial
turn
University of Oxford
Vascular
with COVID-19
[DOI] 10.1186/s12948-020-00132-7 PMC 바로가기 [Article Type] Review
[DOI] 10.1186/s12948-020-00132-7 PMC 바로가기 [Article Type] Review